CINCOR PHARMA INC (CINC) Stock Analyst Ratings
NASDAQ:CINC - Nasdaq - US17240Y1091 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 78% to CINC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 39.78. This target is 36.89% above the current price.
CINC was analyzed by 12 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CINC.
In the previous month the buy percentage consensus was at a similar level.
CINC was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-01-12 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2023-01-10 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-12-08 | Barclays | Initiate | Overweight |
| 2022-12-07 | Barclays | Initiate | Overweight |
| 2022-11-29 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-11-29 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-10-28 | Goldman Sachs | Initiate | Buy |
| 2022-09-09 | Morgan Stanley | Maintains | Overweight |
| 2022-08-22 | Piper Sandler | Initiate | Overweight |
| 2022-08-09 | Morgan Stanley | Maintains | Overweight |
| 2022-07-21 | Oppenheimer | Maintains | Outperform |
| 2022-07-15 | Morgan Stanley | Maintains | Overweight |
| 2022-02-01 | Oppenheimer | Initiate | Outperform |
| 2022-02-01 | Evercore ISI Group | Initiate | Outperform |
| 2022-02-01 | Morgan Stanley | Initiate | Overweight |
| 2022-02-01 | Jefferies | Initiate | Buy |